AEON Biopharma Inc.
AEON | AMEX
$0.48
-$0.02 (-4.52%)
At close: Jul 10, 2026, 3:58 PM ET
Company Profile
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Key Executives
| Name | Position |
|---|---|
| Robert Bancroft | President, Chief Executive Officer & Director |
| John A. Bencich | Chief Financial Officer |
| Alex Wilson | Chief Legal & Strategy Officer and Corporate Secretary |
| Chad K. Oh | Chief Medical Officer |
| Jennifer Sy | Chief Accounting Officer |
AEON Biopharma Inc.
| Country | United States |
| IPO Date | Jul 23, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Robert Bancroft |
Contact Details
4040 Macarthur Boulevard Newport Beach,
California 92614 United States
Stock Details
| Ticker Symbol | AEON |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837607 |
| CUSIP Number | 00791X209 |
| ISIN Number | US00791X2099 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove AEON